Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM 68 Capex-to-Operating-Cash-Flow is 0.07 as of Jun. 2026, which is 82% below its 10-year median of 0.38. GuruFocus rates LTS:0RAM with a GF Score™ of 68/100 and a GF Value™ of kr23.27 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 551 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 76.23% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Vistin Pharma ASA Capex-to-Operating-Cash-Flow Related Terms
Vistin Pharma ASA Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Capex-to-Operating-Cash-Flow Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Capex-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.07 mean?
Vistin Pharma ASA (LTS:0RAM) has a Capex-to-Operating-Cash-Flow of 0.07 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Vistin Pharma ASA and its competitors. This is 82% below median its historical median of 0.38. Over the past decade, Vistin Pharma ASA's Capex-to-Operating-Cash-Flow has ranged from 0.17 to 3.74. According to the industry distribution chart, Vistin Pharma ASA ranks #131 out of 551 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is Vistin Pharma ASA's Capex-to-Operating-Cash-Flow too high?
Vistin Pharma ASA's current Capex-to-Operating-Cash-Flow of 0.07 is 82% below median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 3.74. The Drug Manufacturers industry median Capex-to-Operating-Cash-Flow is 0.37. Vistin Pharma ASA's value of 0.07 is 81.1% below this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #131 out of 551 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Capex-to-Operating-Cash-Flow compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #131 out of 551 companies for Capex-to-Operating-Cash-Flow. This places Vistin Pharma ASA in the top 24% of its industry — outperforming the majority of peers. The industry median Capex-to-Operating-Cash-Flow is 0.37. Vistin Pharma ASA's value of 0.07 is 81.1% below this benchmark. Historically, Vistin Pharma ASA's own Capex-to-Operating-Cash-Flow has ranged from 0.17 to 3.74 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 0.37, Vistin Pharma ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Capex-to-Operating-Cash-Flow among Drug Manufacturers companies is 0.37, based on 551 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Capex-to-Operating-Cash-Flow of 0.07 is 81.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Capex-to-Operating-Cash-Flow is 0.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Capex-to-Operating-Cash-Flow is 0.07, which is 82% below median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr23.27, compared to a current price of kr19.15 — trading 17.7% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.07, which is 82% below median its 10-year median of 0.38 and 81.1% below the Drug Manufacturers industry median of 0.37. Vistin Pharma ASA's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Capex-to-Operating-Cash-Flow is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr19.15 is trading 17.7% below its estimated GF Value™ of kr23.27.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Capex-to-Operating-Cash-Flow: 0.07 (82% below median its 10-year median of 0.38)
GF Value™: kr23.27 vs. price of kr19.15 (17.7% below fair value)
Industry Position: 81.1% below the Drug Manufacturers median (#131 of 551)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
68GF Score
Get the complete analysis for LTS:0RAM
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
